Development an Innovative, Contrarian and Unprecedented Theragnostic Technology based on Submicron Fluorescent Diamond Particles, FDP-NV-750NM Coated with Doxorubicin and Duplex Sorafenib. PART II: - In Vivo Proof of Hypotheses and Technical Feasibil

Feuerstein GZ* , Firestein R, Marcinkiewicz C.

  • Name: Feuerstein GZ*
  • Phone: +1234567890
  • Country: United States of America
  • Received date: 02 February, 2025
  • Accepted date: 19 May, 2025
  • Published date: 26 May, 2025

Designation: FARMACON LLC, San Diego, California, USA

Citation: Feuerstein GZ, Firestein R, Marcinkiewicz C (2025) Development an Innovative, Contrarian and Unprecedented Theragnostic Technology based on Submicron Fluorescent Diamond Particles, FDP-NV-750NM Coated with Doxorubicin and Duplex Sorafenib. PART II: - In Vivo Proof of Hypotheses and Technical Feasibility for Direct to Tumor Injection of FDP-NV-DOX~SOR to Xenograft Tumors in Immune Compromised BALB/C2 ‘NUDE’ Mice. Int J Nano Rech Vol: 8, Issu: 1 (01-19).

Copyright: © 2025 Feuerstein GZ et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Fulltext Under Construction
Facebook
Twitter
LinkedIn